1. 3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. (September 2015) Authors: Cadranel, J.; Quoix, E.; Duruisseaux, M.; Friard, S.; Fabre, E.; Daniel, C.; Westeel, V.; Madroszyk, A.; Lena, H.; Merle, P.; Mazieres, J.; Dansin, E.; Scherpereel, A.; Hiret, S.; Coudert, B.; Souquet, P.J.; Missy, P.; Morin, F.; Zalcman, G.; Barlesi, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S646 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab-refractory patients with advanced non-small-cell lung cancer. (April 2019) Authors: Costantini, A.; Fallet, V.; Corny, J.; Friard, S.; Chouaid, C.; Duchemann, B.; Giroux-Leprieur, E.; Taillade, L.; Doucet, L.; Brosseau, S.; Wislez, M.; Tredaniel, J.; Cadranel, J. Journal: Lung cancer Issue: Volume 130(2019) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗